JP2021019642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021019642A5 JP2021019642A5 JP2020184527A JP2020184527A JP2021019642A5 JP 2021019642 A5 JP2021019642 A5 JP 2021019642A5 JP 2020184527 A JP2020184527 A JP 2020184527A JP 2020184527 A JP2020184527 A JP 2020184527A JP 2021019642 A5 JP2021019642 A5 JP 2021019642A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 12
- 108090001123 antibodies Proteins 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 210000004962 mammalian cells Anatomy 0.000 claims 6
- 229920000023 polynucleotide Polymers 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
Claims (5)
- （ｉ）配列番号１のアミノ酸配列によって定められる抗体重鎖をコードするポリヌクレオチドを含むＤＮＡ分子、および
（ｉｉ）配列番号２のアミノ酸配列によって定められる抗体軽鎖をコードするポリヌクレオチドを含むＤＮＡ分子
を含む、哺乳動物細胞であって、
前記細胞が、２つの重鎖および２つの軽鎖を含む抗体を発現することができ、各重鎖のアミノ酸配列が配列番号１によって定められ、各軽鎖のアミノ酸配列が配列番号２によって定められる、哺乳動物細胞。 - 配列番号１のアミノ酸配列を有する抗体重鎖をコードするポリヌクレオチド配列および配列番号２のアミノ酸配列を有する抗体軽鎖をコードするポリヌクレオチド配列を含むＤＮＡ分子を含む、哺乳動物細胞であって、前記細胞が、２つの重鎖および２つの軽鎖を含む抗体を発現することができ、各重鎖のアミノ酸配列が配列番号１によって定められ、各軽鎖のアミノ酸配列が配列番号２によって定められる、哺乳動物細胞。
- 前記抗体重鎖をコードするポリヌクレオチド配列が、配列番号３５であり、前記抗体軽鎖をコードするポリヌクレオチド配列が、配列番号３６である、請求項２に記載の哺乳動物細胞。
- 抗体を産生するための方法であって、２つの重鎖（ＨＣ）のそれぞれのアミノ配列が配列番号１であり、２つの軽鎖（ＬＣ）のそれぞれのアミノ酸配列が配列番号２であり、ａ）請求項１〜３のいずれか１項に記載の哺乳動物細胞を前記抗体が発現される条件下で培養し、次いでｂ）前記発現された抗体を回収することを含む、方法。
- 請求項４に記載の方法によって得られる抗体。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508510P | 2017-05-19 | 2017-05-19 | |
| US62/508,510 | 2017-05-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511876A Division JP6790304B2 (ja) | 2017-05-19 | 2018-05-11 | Ｂｔｌａアゴニスト抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021019642A JP2021019642A (ja) | 2021-02-18 |
| JP2021019642A5 true JP2021019642A5 (ja) | 2021-07-26 |
| JP7072622B2 JP7072622B2 (ja) | 2022-05-20 |
Family
ID=62245543
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511876A Active JP6790304B2 (ja) | 2017-05-19 | 2018-05-11 | Ｂｔｌａアゴニスト抗体およびその使用 |
| JP2020184527A Active JP7072622B2 (ja) | 2017-05-19 | 2020-11-04 | Ｂｔｌａアゴニスト抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511876A Active JP6790304B2 (ja) | 2017-05-19 | 2018-05-11 | Ｂｔｌａアゴニスト抗体およびその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10604573B2 (ja) |
| EP (1) | EP3625257A1 (ja) |
| JP (2) | JP6790304B2 (ja) |
| KR (3) | KR102294051B1 (ja) |
| CN (3) | CN117402244A (ja) |
| AR (1) | AR111752A1 (ja) |
| AU (2) | AU2018269585B2 (ja) |
| BR (1) | BR112019021547A2 (ja) |
| CA (2) | CA3184628A1 (ja) |
| CL (1) | CL2019003215A1 (ja) |
| CO (1) | CO2019012756A2 (ja) |
| CR (1) | CR20190521A (ja) |
| DO (1) | DOP2019000293A (ja) |
| EA (1) | EA201992460A1 (ja) |
| EC (1) | ECSP19082184A (ja) |
| JO (1) | JOP20190261A1 (ja) |
| MA (1) | MA49133A (ja) |
| MX (1) | MX2019013604A (ja) |
| MY (1) | MY197425A (ja) |
| NZ (1) | NZ758360A (ja) |
| PE (1) | PE20191843A1 (ja) |
| PH (1) | PH12019502575A1 (ja) |
| TW (4) | TWI804044B (ja) |
| WO (1) | WO2018213113A1 (ja) |
| ZA (1) | ZA201906954B (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201820554D0 (en) * | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
| CN114555792A (zh) | 2019-10-15 | 2022-05-27 | 伊莱利利公司 | 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系 |
| GB202008860D0 (en) | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
| IL302135A (en) * | 2020-10-23 | 2023-06-01 | Anaptysbio Inc | B and T lymphocyte attenuating modulators and methods of using them |
| WO2023143565A1 (en) * | 2022-01-29 | 2023-08-03 | Hifibio (Hk) Limited | Anti-btla antibodies and uses thereof in treating cancer |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8546541B2 (en) * | 2002-06-20 | 2013-10-01 | Washington University | Compositions and methods for modulating lymphocyte activity |
| ES2577532T3 (es) * | 2002-10-25 | 2016-07-15 | Genentech, Inc. | Nueva composición y métodos para el tratamiento de enfermedades relacionadas con el sistema inmune |
| WO2008076560A2 (en) * | 2006-11-15 | 2008-06-26 | Medarex, Inc. | Human monoclonal antibodies to btla and methods of use |
| BR112012007875A2 (pt) * | 2009-07-31 | 2016-11-22 | Medarex Inc | anticorpos totalmente humanos para btla |
| US9533039B2 (en) * | 2010-09-27 | 2017-01-03 | Regeneron Pharmaceuticals, Inc. | Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies |
| WO2014018931A1 (en) * | 2012-07-26 | 2014-01-30 | The General Hospital Corporation | Methods and compositions for treating autoimmune disease |
| WO2014183885A1 (en) * | 2013-05-17 | 2014-11-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of the btla/hvem interaction for use in therapy |
| US11352428B2 (en) * | 2015-04-29 | 2022-06-07 | Sanford Burnham Prebys Medical Discovery Institute | Modulation of immune response using BTLA agonist antibodies |
| US11253590B2 (en) * | 2015-12-02 | 2022-02-22 | Stsciences, Inc. | Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator) |
-
2017
- 2017-06-16 JO JOP/2019/0261A patent/JOP20190261A1/ar unknown
-
2018
- 2018-05-03 AR ARP180101158A patent/AR111752A1/es unknown
- 2018-05-04 TW TW110141711A patent/TWI804044B/zh active
- 2018-05-04 TW TW112116965A patent/TW202334237A/zh unknown
- 2018-05-04 TW TW107115166A patent/TWI677504B/zh active
- 2018-05-04 TW TW108133289A patent/TWI747043B/zh active
- 2018-05-11 PE PE2019002417A patent/PE20191843A1/es unknown
- 2018-05-11 MY MYPI2019006702A patent/MY197425A/en unknown
- 2018-05-11 KR KR1020197033639A patent/KR102294051B1/ko active Application Filing
- 2018-05-11 BR BR112019021547-6A patent/BR112019021547A2/pt unknown
- 2018-05-11 CN CN202311364321.5A patent/CN117402244A/zh active Pending
- 2018-05-11 US US15/977,003 patent/US10604573B2/en active Active
- 2018-05-11 EP EP18727622.5A patent/EP3625257A1/en active Pending
- 2018-05-11 WO PCT/US2018/032218 patent/WO2018213113A1/en active Application Filing
- 2018-05-11 MA MA049133A patent/MA49133A/fr unknown
- 2018-05-11 CA CA3184628A patent/CA3184628A1/en active Pending
- 2018-05-11 MX MX2019013604A patent/MX2019013604A/es unknown
- 2018-05-11 CA CA3064518A patent/CA3064518A1/en active Pending
- 2018-05-11 CN CN201880033180.XA patent/CN110621699B/zh active Active
- 2018-05-11 JP JP2020511876A patent/JP6790304B2/ja active Active
- 2018-05-11 CN CN202311364322.XA patent/CN117402245A/zh active Pending
- 2018-05-11 EA EA201992460A patent/EA201992460A1/ru unknown
- 2018-05-11 NZ NZ758360A patent/NZ758360A/en unknown
- 2018-05-11 CR CR20190521A patent/CR20190521A/es unknown
- 2018-05-11 KR KR1020217026470A patent/KR20210106033A/ko not_active Application Discontinuation
- 2018-05-11 KR KR1020227039792A patent/KR20220158847A/ko not_active Application Discontinuation
- 2018-05-11 AU AU2018269585A patent/AU2018269585B2/en active Active
-
2019
- 2019-10-22 ZA ZA2019/06954A patent/ZA201906954B/en unknown
- 2019-11-08 CL CL2019003215A patent/CL2019003215A1/es unknown
- 2019-11-15 DO DO2019000293A patent/DOP2019000293A/es unknown
- 2019-11-15 CO CONC2019/0012756A patent/CO2019012756A2/es unknown
- 2019-11-18 PH PH12019502575A patent/PH12019502575A1/en unknown
- 2019-11-18 EC ECSENADI201982184A patent/ECSP19082184A/es unknown
-
2020
- 2020-02-17 US US16/792,396 patent/US11396545B2/en active Active
- 2020-11-04 JP JP2020184527A patent/JP7072622B2/ja active Active
-
2021
- 2021-12-02 AU AU2021277743A patent/AU2021277743A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021019642A5 (ja) | ||
| JP2021151253A5 (ja) | ||
| AR120511A2 (es) | Producción de proteínas heteromultiméricas | |
| JP2022169664A5 (ja) | ||
| RU2015148746A (ru) | Новый способ клонирования, экспрессии и очистки для получения ранибизумаба | |
| CN104131105B (zh) | 一种特异性结合甲胎蛋白核酸适配体的筛选方法 | |
| JP2008500050A5 (ja) | ||
| HRP20211882T1 (hr) | Protutijela protiv cd40 i njihova upotreba | |
| JP2009082138A5 (ja) | ||
| JP2005120106A5 (ja) | ||
| RU2009137582A (ru) | Инженерия и оптимизация одноцепочечных антител на основе последовательности | |
| HRP20180155T1 (hr) | Novo protutijelo protiv ljudskog ngf | |
| JP2011524740A5 (ja) | ||
| JP2010516239A5 (ja) | ||
| ATE514717T1 (de) | Rekombinante produktion von antikörpermischungen | |
| CA2532966A1 (en) | Igm production by transformed cells and methods for quantifying said igm production | |
| HRP20181047T1 (hr) | Protutijela protiv kemokina pan-elr+ cxc | |
| JP2011525355A5 (ja) | ||
| DE502006009060D1 (de) | Verfahren zur fermentativen Herstellung von Antikörpern | |
| JP2011024493A5 (ja) | ||
| RU2010119558A (ru) | Способ получения клетки, способной продуцировать гетепротеины с высоким выходом | |
| JP2015532096A5 (ja) | ||
| JP2013544069A5 (ja) | ||
| JP2011501970A5 (ja) | ||
| JP2011505811A5 (ja) |